CLINICAL IMMUNOSUPPRESSION - KIDNEY LATE

M. Rengel¹, . Verdalles², A. Vega², S. Abad², E. Verde^2
1Nephrology, Hospital General Universitario Gregorio Marañón, Madrid/SPAIN, ²Nephrology, Hospital General Universitario, Madrid/SPAIN

Body: Introduction:Everolimus is a proliferation signal inhibitor utilized as immunosupressant in combination with CNI in renal transplantation. The present paper reports ourexperience with renal grafted patients treated with CNI who were switched to EVE in order to avoid CNI nephrotoxicity. Methods:From february 2005, 120 cadaver kidney graftedpatients (82 men and 38 women) were switched from CNI to EVE. The age of the patients was 56+/-15 years, with 8.5+/-6 years (1-23) followup period. The immunosuppression treatment was based onPrednisone, Mycophenolate Mophetil/Sodium Mycophenolic Acid and Tacrolimus/Cyclosporine. CNI was stopped according to an abrupt conversion protocol. EVE was started at 1.0 mg day divided in two dosesand blood concentration was maintained between 3-5 ng/ml. Results: At 2 year patient and graft survival was 100% and there were not acute rejection episodes. Blood presure showsno changes and there were not changes in glucose metabolism. Lipids increased slightly during the first three months after EVE treatment. Proteinuria apear in patients with previos glomerularlesions. GFR improved in 55% of patients. In conclusion: conversion from CNI to EVE in renal transplant patients is safe and affect slightly to lipids metabolism

Disclosure: All authors have declared no conflicts of interest.